Femasys Inc.

FEMY Nasdaq SEC CIK 1339005
Follow Femasys Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $404.6K −44.5% vs same quarter last year
Net income −$4.6M −8.8% vs same quarter last year
EPS, diluted −$0.53 +74.1% vs same quarter last year
Operating cash flow −$4.8M +10.6% vs same quarter last year
Revenue by quarter
$581.6K
$341.3K
$409.3K
$729.4K
$813.4K
$424.9K
$331.8K
$404.6K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$20M−$10M$0$10MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$2.3M−$18.6M
FY24$1.6M−$18.8M
FY23$1.1M−$14.2M
FY22$1.2M−$11.4M
FY21$1.2M−$7.5M
FY20$1M−$6.9M
FY19--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2562%−767%−812.3%
FY2466.6%−1091.8%−1155%
FY2364.5%−1353.4%−1329.1%
FY2263.4%−961.7%−944.6%
FY2168.6%−706.7%−639%
FY2070.5%−668%−666.2%
FY19---
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$19.2M
FY24−$20.2M
FY23−$11.4M
FY22−$11.1M
FY21−$8.2M
FY20−$4.9M
FY19-
Returned to shareholdersDividends paid and shares bought back
$0$100K$200K$300KFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25-
FY24$60.8K
FY23$230K
FY22$0
FY21-
FY20-
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Femasys
  • Healthcare median
−1500%−1000%−500%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFemasysHealthcare median
FY25−812.3%−30.6%
FY24−1155%−47%
FY23−1329.1%−58%
FY22−944.6%−80.4%
FY21−639%−71.8%
FY20−666.2%−62.2%
FY19-−46.2%